DESIGNING COORDINATED IMMUNOTHERAPY
The immune response to disease is dynamic and complex. While most companies focus on a single aspect of immunity, CytoImmune Therapeutics takes a different approach.
We’ve developed a coordinated immunotherapy platform that combines the most innovative technology – chimeric antigen receptors (CARs) and bispecific antibodies (biAbs) – with the most powerful immune cell types – T cells and natural killer (NK) cells – to expedite and personalize patient care.
|PRODUCT CANDIDATE||TECHNOLOGY||Coalescent™ Platform||Cell Type||Target/Indication||Preclinical||IND Submitted||Phase I|
|FLT3 CAR||Lentivirus||No||T||FLT3/AML||Completed||No||March 2020|
|EGFR CAR||Retro or Lentivirus||No||NK||EGFR GBM||Ongoing||No||No|
|CS1 BiAb-BCMA CAR||Lentivirus||Yes||T||CS1/BCMA MM||Ongoing||No||March 2020|
AML – acute myeloid leukemia; GMB – glioblastoma; MM – multiple myeloma